Analysts Offer Predictions for Myovant Sciences Ltd.’s FY2026 Earnings (NYSE:MYOV)

Myovant Sciences Ltd. (NYSE:MYOVGet Rating) – Stock analysts at SVB Leerink cut their FY2026 EPS estimates for Myovant Sciences in a report released on Tuesday, August 2nd. SVB Leerink analyst R. Ruiz now forecasts that the company will post earnings per share of $0.35 for the year, down from their previous estimate of $0.40. SVB Leerink has a “Market Perform” rating and a $12.00 price objective on the stock. The consensus estimate for Myovant Sciences’ current full-year earnings is ($1.91) per share.

Myovant Sciences (NYSE:MYOVGet Rating) last released its quarterly earnings results on Tuesday, May 10th. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.08). The business had revenue of $57.57 million for the quarter, compared to analyst estimates of $60.76 million.

Other analysts also recently issued reports about the stock. Robert W. Baird decreased their price objective on shares of Myovant Sciences from $30.00 to $20.00 in a research report on Wednesday, April 13th. The Goldman Sachs Group raised their price objective on shares of Myovant Sciences from $9.00 to $10.00 and gave the company a “neutral” rating in a research report on Thursday, July 28th.

Myovant Sciences Price Performance

Shares of MYOV stock opened at $14.65 on Wednesday. The company has a market capitalization of $1.41 billion, a price-to-earnings ratio of -8.32 and a beta of 2.40. Myovant Sciences has a one year low of $7.67 and a one year high of $27.43. The company’s fifty day moving average price is $12.33 and its 200-day moving average price is $12.15.

Hedge Funds Weigh In On Myovant Sciences

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Bellevue Group AG grew its stake in shares of Myovant Sciences by 6.9% in the 4th quarter. Bellevue Group AG now owns 6,169,039 shares of the company’s stock worth $96,052,000 after buying an additional 400,000 shares in the last quarter. State Street Corp boosted its stake in shares of Myovant Sciences by 16.2% during the 1st quarter. State Street Corp now owns 3,334,935 shares of the company’s stock worth $44,421,000 after purchasing an additional 464,627 shares during the period. BlackRock Inc. boosted its stake in shares of Myovant Sciences by 3.5% during the 1st quarter. BlackRock Inc. now owns 1,202,975 shares of the company’s stock worth $16,023,000 after purchasing an additional 41,087 shares during the period. Pier Capital LLC boosted its stake in shares of Myovant Sciences by 1.1% during the 4th quarter. Pier Capital LLC now owns 296,166 shares of the company’s stock worth $4,611,000 after purchasing an additional 3,190 shares during the period. Finally, Rafferty Asset Management LLC boosted its stake in shares of Myovant Sciences by 121.7% during the 4th quarter. Rafferty Asset Management LLC now owns 252,190 shares of the company’s stock worth $3,927,000 after purchasing an additional 138,428 shares during the period. 32.55% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Myovant Sciences

In other Myovant Sciences news, insider Ferreira Juan Camilo Arjona sold 2,755 shares of Myovant Sciences stock in a transaction on Wednesday, July 6th. The shares were sold at an average price of $13.40, for a total value of $36,917.00. Following the sale, the insider now directly owns 255,992 shares in the company, valued at approximately $3,430,292.80. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other Myovant Sciences news, General Counsel Matthew Lang sold 3,702 shares of Myovant Sciences stock in a transaction on Wednesday, July 6th. The shares were sold at an average price of $13.40, for a total value of $49,606.80. Following the completion of the transaction, the general counsel now directly owns 272,335 shares of the company’s stock, valued at approximately $3,649,289. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Ferreira Juan Camilo Arjona sold 2,755 shares of Myovant Sciences stock in a transaction on Wednesday, July 6th. The stock was sold at an average price of $13.40, for a total transaction of $36,917.00. Following the completion of the transaction, the insider now directly owns 255,992 shares of the company’s stock, valued at $3,430,292.80. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 10,096 shares of company stock worth $133,358. Insiders own 1.90% of the company’s stock.

About Myovant Sciences

(Get Rating)

Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer.

See Also

Earnings History and Estimates for Myovant Sciences (NYSE:MYOV)

Receive News & Ratings for Myovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.